Form 8-K RAPT Therapeutics, Inc. For: May 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
May 9, 2024 4:03 PM EDTGuggenheim analyst Yatin Suneja downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral.
The analyst comments "Key takeaways from our call with RAPT mgmt. include: (1) database cleaning is underway for both atopic dermatitis and asthma studies of RPT-193 (oral CCR4 blocker; recall that in Feb 2024, both clinical studies were put on... More



